role
virus
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
need
elucid
aim
present
studi
evalu
molecular
epidemiolog
viral
pathogen
aecopd
patient
present
emerg
room
aecopd
need
hospit
recruit
oropharyng
sputum
sampl
collect
order
perform
microarraysbas
viral
test
detect
respiratori
virus
total
patient
analyz
viru
detect
commonest
identifi
virus
human
respiratori
syncyti
viru
subtyp
b
influenza
viru
subtyp
b
c
rhinoviru
human
parainfluenza
viru
subtyp
b
bacteri
pathogen
isol
patient
dual
infect
due
bacteri
viral
pathogen
recognis
patient
patient
aecopd
viral
infect
lengthier
hospit
stay
ae
vs
ae
p
sever
diseas
relat
signific
differ
among
group
studi
popul
conclus
isol
viru
strongli
associ
aecopd
examin
popul
stage
copd
appear
relat
frequenc
isol
virus
dual
infect
viral
bacteri
pathogen
rare
chronic
obstruct
pulmonari
diseas
copd
frequent
complic
recurr
exacerb
call
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
event
associ
high
morbid
increas
health
care
expenditur
reduc
health
statu
patient
main
risk
factor
associ
aecopd
occurr
respiratori
infect
although
multipl
factor
contribut
potenti
process
industri
pollut
allergen
sed
comorbid
frequent
present
patient
aecopd
reportedli
caus
viru
bacteri
infect
mainli
due
haemophilu
influenza
streptococcu
pneumonia
moraxella
catarrhali
haemophiu
parainfluenza
pseudomona
aeruginosa
stenotrophomona
maltophilia
staphylococcu
aureu
respons
approxim
event
import
viral
infect
aecopd
recogn
evolut
newer
molecular
diagnost
method
sinc
tradit
diagnost
techniqu
eg
direct
immunofluoresc
cultur
etc
consid
slow
regard
final
result
present
low
sensit
threshold
profil
unabl
quickli
identifi
common
emerg
virus
moreov
tradit
techniqu
may
fail
identifi
specif
pathogen
human
metapneumoviru
detect
serolog
viral
cultur
develop
nucleic
acid
amplif
test
enabl
time
accur
detect
respiratori
virus
test
develop
respiratori
virus
includ
tradit
emerg
strain
recent
develop
dnarna
microarray
enabl
identif
multipl
gene
target
singl
pathogen
multipl
pathogen
singl
clinic
sampl
aim
studi
assess
epidemiolog
viral
infect
potenti
contribut
aecopd
patient
requir
hospit
use
new
pcrbase
array
techniqu
patient
consecut
examin
emerg
depart
er
tertiari
care
hospit
sotiria
hospit
athen
greec
diagnos
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
includ
studi
period
extend
januari
decemb
adult
patient
year
confirm
diagnosi
copd
classifi
accord
gold
criteria
requir
hospit
admiss
aecopd
includ
aecopd
defin
acut
onset
event
natur
cours
copd
character
chang
patient
baselin
dyspnea
cough
sputum
beyond
normal
daytoday
variat
usual
requir
modif
regular
medic
stabl
copd
cours
patient
confirm
diagnosi
bronchial
asthma
avail
spirometr
data
exclud
studi
approv
ethic
committe
hospit
written
inform
consent
obtain
recruit
patient
immedi
initi
evalu
er
detail
medic
histori
obtain
patient
demograph
includ
age
sex
sever
diseas
copd
stage
smoke
habit
need
oxygen
therapi
influenza
vaccin
comorbid
use
inhal
steroid
record
patient
includ
studi
underw
part
evalu
complet
blood
count
measur
serum
c
reactiv
protein
crp
level
chestxray
arteri
blood
gase
abg
analysi
sputum
cultur
sent
common
bacteria
blood
cultur
obtain
respons
physician
consid
appropri
classif
patient
use
avail
spirometr
data
last
three
month
patient
abl
perform
spirometri
initi
evalu
spirometri
prepost
bronchodil
perform
discharg
hospit
result
compar
avail
spirometr
result
last
three
month
way
certain
correct
classif
patient
stage
mild
copd
patient
fev
fvc
fev
predict
valu
stage
ii
moder
copd
patient
fev
fvc
fev
predict
valu
stage
iii
sever
copd
patient
fev
fvc
fev
predict
valu
stage
iv
sever
copd
patient
fev
fvc
fev
predict
valu
fev
valu
predict
plu
chronic
respiratori
failur
gold
criteria
initi
evalu
administr
treatment
sputum
oropharyng
sampl
collect
microarray
techniqu
perform
detect
virus
clart
pneumovir
kit
genomica
spain
use
method
detect
frequent
type
human
virus
caus
respiratori
infect
identifi
minimum
quantiti
viral
genom
materi
use
sequenc
correspond
highli
preserv
region
within
viral
genom
bind
probe
specif
respiratori
viru
type
virus
analyz
includ
influenza
viru
type
b
c
solut
centrifug
g
molecular
procedur
follow
accord
manufactur
instruct
briefli
viral
dnarna
extract
use
ml
clinic
sampl
mix
lysi
buffer
allow
stand
min
follow
addit
isopropanol
centrifug
rpm
min
supernat
remov
precipit
resuspend
ml
ethanol
follow
centrifug
rpm
min
supernat
remov
sampl
left
dri
min
ethanol
residu
left
lastli
pellet
resuspend
ml
dilut
solut
viral
dna
rna
extract
store
c
amplif
viru
amplif
perform
via
two
rt
revers
transcriptas
multiplex
pcr
reaction
specif
bp
fragment
viral
genom
pcr
employ
follow
thermal
cycler
set
cycl
min
c
min
c
follow
cycl
c
min
c
min
c
final
cycl
min
c
visual
amplifi
product
perform
platform
base
lowdens
microarray
socal
arraytub
detect
system
base
precipit
insolubl
product
site
hybrid
product
amplifi
specif
molecular
probe
produc
rtpcr
amplifi
product
label
biotin
follow
amplif
hybrid
respect
specif
probe
immobil
concret
known
site
incub
streptavidinperoxidas
conjug
conjug
bind
via
streptavidin
biotin
present
amplifi
product
also
bound
specif
probe
presenc
odianisidin
peroxidas
activ
conjug
induc
appear
insolubl
product
precipit
hybrid
site
normal
distribut
continu
data
summar
mean
ae
standard
deviat
sd
wherea
nonnorm
distribut
data
median
interquartil
rang
iqr
categor
data
summar
rate
nonparametr
test
mann
whitney
assess
differ
continu
variabl
copd
group
categor
variabl
compar
chisquar
test
p
valu
less
consid
signific
test
twotail
data
analyz
use
statist
softwar
spss
version
spss
chicago
il
total
patient
met
inclus
criteria
er
present
patient
increas
dyspnea
cough
product
purul
sputum
report
fever
symptom
somnol
excit
report
patient
symptom
appear
averag
ae
day
er
evalu
patient
abl
perform
spirometri
er
order
classifi
accord
gold
criteria
rest
classifi
use
recent
avail
spirometr
data
sinc
unabl
perform
spirometri
due
sever
diseas
comorbid
condit
note
follow
order
frequenc
patient
report
histori
chronic
cardiac
diseas
patient
known
diabet
mellitu
patient
histori
chronic
renal
failur
patient
viru
identifi
array
least
one
collect
specimen
either
orophryng
sputum
sampl
viru
isol
mix
infect
one
viral
pathogen
identifi
patient
tabl
differ
note
copd
group
regard
isol
viru
group
differ
length
hospit
stay
longer
copd
patient
viru
isol
p
tabl
patient
bacteri
pathogen
identifi
sputum
cultur
twelv
patient
surviv
tabl
isol
virus
order
frequenc
human
respiratori
suncyti
viru
hrsv
subtyp
b
influenza
type
b
c
viru
rhinoviru
human
parainfluenza
hpiv
subtyp
coronaviru
human
metapneumoviru
hmpva
subtyp
b
adenoviru
enteroviru
fig
signific
discrep
note
isol
virus
oropharyng
sputum
sampl
rsv
detect
array
oropharyng
sampl
viru
detect
concomitantli
taken
sputum
sampl
convers
rsv
identifi
collect
sputum
sampl
wherea
found
simultan
taken
sampl
oropharynx
case
overal
viru
found
sampl
rhinoviru
success
isol
oropharyng
sampl
wherea
hpiv
influenza
virus
sputum
data
shown
vast
major
posit
sampl
note
januari
april
octob
patient
characterist
accord
copd
stage
shown
tabl
patient
recruit
studi
die
state
tabl
death
relat
presenc
viral
infect
p
state
tabl
also
relat
stage
diseas
p
risk
factor
found
relat
nonsurviv
use
oxygen
seem
patient
surviv
oxygen
depend
result
statist
import
p
comorbid
ex
cardiac
diseas
renal
failur
diabet
mellitu
seem
risk
factor
neg
outcom
aecopd
patient
viru
isol
simultan
posit
bacteri
cultur
note
specif
patient
pseudomona
aeruginosa
cultur
haemophilu
influenza
klebsiella
pneumonia
staphylococcu
aureu
acinetobact
baumanii
stenotrophomomona
maltophilia
bacteria
one
patient
bacteri
pathogen
identifi
tabl
bacteri
cultur
frequent
posit
patient
copd
stage
iiiiv
copd
patient
stage
ii
p
tabl
studi
includ
larg
number
patient
greec
admit
hospit
sever
exacerb
copd
examin
sampl
upper
lower
respiratori
tract
compar
result
literatur
limit
small
studi
first
knowledg
assess
epidemiolog
respiratori
virus
popul
countri
main
find
studi
aecopd
patient
requir
hospit
high
rate
respiratori
viru
infect
detect
b
higher
frequenc
isol
note
specif
virus
c
sever
diseas
associ
higher
detect
rate
virus
well
known
aecopd
trigger
viral
infect
preval
winter
month
caus
sever
exacerb
character
longer
recoveri
period
exacerb
trigger
factor
studi
high
detect
rate
virus
note
result
increas
sensit
appli
pcrbase
techniqu
avail
diagnost
method
serolog
viral
cultur
pcr
present
differ
rate
sensit
detect
respiratori
virus
sensit
vari
depend
sampl
obtain
tropism
viru
nasopharyng
aspir
nasal
oropharyng
nosethroat
swab
variabl
observ
studi
other
claim
use
pcr
realtim
pcr
techniqu
may
help
overcom
effect
role
viru
tropism
may
signific
factor
howev
highest
rate
rhinovirus
discov
oropharyng
sputum
sampl
studi
studi
nasal
secret
altern
sputum
sampl
viru
concomit
posit
oropharyng
sampl
may
denot
upper
lower
airway
infect
clearli
work
look
explan
similar
discrep
detect
rate
respiratori
virus
studi
compar
studi
although
differ
could
explain
differ
period
sampl
prolong
length
hospit
stay
patient
could
explain
intens
system
inflammatori
respons
character
mainli
increas
crp
blood
leucocyt
howev
neither
crp
number
blood
leucocyt
significantli
differ
patient
without
viru
commonest
isol
virus
cohort
hrsv
type
b
influenza
viru
rhinoviru
role
hrsv
well
recogn
major
caus
respiratori
infect
infant
young
children
signific
caus
morbid
mortal
adult
copd
patient
studi
hrsv
predomin
viru
detect
oropharyng
sputum
sampl
could
explain
fact
acut
respiratori
infect
hrsv
viru
frequent
persist
respiratori
tract
low
viral
load
detect
later
patient
stabl
copd
lead
declin
lung
function
frequent
exacerb
patient
quantit
pcr
avail
order
identifi
viral
load
reason
abl
clarifi
viru
actual
causal
relat
aecopd
reflect
chronic
colon
patient
rel
high
rate
influenza
viru
isol
could
explain
observ
lower
influenza
vaccin
rate
relat
studi
howev
differ
note
immun
nonimmun
patient
probabl
vari
antibodi
respons
vaccin
subject
rhinoviru
major
caus
common
cold
consid
major
pathogen
aecb
studi
detect
rate
smaller
hrsv
influenza
viru
probabl
season
variabl
circul
virus
although
perform
studi
twoyear
period
order
avoid
season
bia
posit
sampl
collect
period
late
autumn
winter
human
metapneumoviru
newli
emerg
pathogen
initi
detect
dutch
children
bronchiol
consid
close
hrsv
studi
viru
identifi
patient
present
detect
rate
similar
one
report
rohd
et
al
asymptomat
carriag
viru
unlik
detect
aecopd
winter
correl
isol
rate
respiratori
virus
sever
diseas
patient
aecopd
identifi
although
avail
data
limit
mcmanu
et
al
report
copd
patient
higher
carriag
rate
virus
comparison
healthi
individu
could
explain
delay
seek
medic
care
patient
relat
appear
symptom
season
respiratori
viral
infect
hand
isol
rate
bacteri
pathogen
studi
lower
total
studi
differ
observ
aecopd
patient
without
viral
detect
detect
bacteri
pathogen
higher
patient
sever
diseas
copd
stage
iiiiv
vs
low
detect
rate
bacteri
pathogen
relat
report
could
explain
low
yield
sputum
cultur
could
also
laboratori
depend
hand
higher
detect
rate
patient
sever
diseas
vs
could
explain
fact
patient
sever
copd
frequent
hospit
excess
use
antibiot
outpati
although
approach
consid
appropri
make
suscept
subsequ
bacteri
infect
multiresist
pathogen
thu
bacteri
data
interpret
caution
low
rate
bacteri
detect
also
reason
perform
analysi
examin
bacteri
infect
commonest
bacteri
pathogen
p
aeruginosa
probabl
major
recruit
patient
belong
copd
stage
iii
iv
mix
infect
bacteri
viral
pathogen
identifi
small
percentag
cohort
patient
p
aeruginosa
h
influenza
also
commonest
detect
bacteri
pathogen
dual
infect
bacteri
pathogen
hrsv
frequent
observ
virus
could
explain
fact
hrsv
like
virus
alter
express
receptor
molecul
respiratori
epitheli
cell
allow
therefor
increas
bacteri
adher
invas
addit
protein
call
hrsv
g
work
cell
receptor
h
influenza
streptococcu
pneumonia
facilit
bacteri
bind
cell
infect
viru
altern
anteced
bacteri
infect
may
increas
suscept
viral
infect
increas
express
hostcel
molecul
bind
virus
pcrbase
techniqu
seem
higher
yield
recov
virus
sputum
rather
nasal
aspir
seen
studi
howev
one
main
drawback
detect
genet
amplif
frequent
observ
fals
neg
result
attribut
poor
qualiti
extract
dnarna
caus
insuffici
quantiti
initi
sampl
degrad
viru
genet
materi
due
inadequ
storag
said
sampl
loss
extract
b
presenc
inhibitor
enzym
mixtur
rt
dna
polymeras
sampl
viru
detect
go
perform
hemoglobin
salt
etc
fals
neg
result
seem
elimin
thank
addit
intern
control
clinic
sampl
confirm
correct
effici
extract
pcr
amplif
reaction
cohort
use
pcrbase
array
techniqu
abl
detect
frequent
type
human
virus
potenti
caus
respiratori
infect
assay
need
valid
prospect
studi
present
studi
number
limit
first
quantit
pcr
avail
order
estim
viral
load
clarifi
patient
carrier
specif
viru
especi
hrsv
true
infect
studi
patient
stabl
copd
recruit
control
subject
thu
sure
whether
virus
identifi
sputum
oropharyng
sampl
caus
exacerb
whether
repres
chronic
colonizationinfect
previou
studi
seemung
et
al
nonrsv
respiratori
virus
detect
rsv
stabl
copd
patient
rate
viru
identif
patient
stabl
copd
much
lower
exacerb
rsv
infect
associ
symptomat
respiratori
ill
togeth
intens
inflammatori
respons
rsv
group
patient
character
increas
crp
level
ae
valu
number
leucocyt
ae
valu
highli
like
viral
infect
play
import
role
trigger
copd
exacerb
moreov
could
adequ
evalu
differ
posit
rate
sampl
test
differ
observ
might
even
greater
nasal
sampl
larger
studi
evalu
sampl
sever
site
take
account
viral
tropism
specif
site
respiratori
tract
assist
regard
furthermor
due
design
studi
inform
provid
concern
specif
test
virus
posit
neg
control
signific
limit
studi
lack
baselin
recoveryconvalesc
evalu
stabl
condit
absenc
control
condit
find
exacerb
care
interpret
sinc
exclud
pathogen
alreadi
present
stabil
lastli
could
account
residu
confound
regard
risk
factor
viru
isol
conclus
use
molecular
assay
method
evalu
viral
epidemiolog
aecopd
patient
singl
center
viral
infect
strongli
relat
aecopd
associ
lengthier
hospit
stay
patient
howev
stage
copd
relat
frequenc
viru
isol
studi
regard
role
viral
infect
copd
cours
necessari
order
develop
new
algorithm
pathogendirect
treatment
copd
exacerb
lead
eas
health
burden
aecopd
chang
qualiti
life
patient
